microb
made
phenomen
contribut
health
wellb
peopl
throughout
world
addit
produc
mani
primari
metabolit
amino
acid
vitamin
nucleotid
capabl
make
secondari
metabolit
constitut
half
pharmaceut
market
today
provid
agricultur
mani
essenti
product
review
center
benefici
secondari
metabolit
discoveri
goe
back
year
time
penicillin
discov
alexand
fleme
back
alexand
fleme
began
microbi
drug
era
discov
petri
dish
seed
staphylococcu
aureu
compound
produc
mold
kill
bacteria
mold
identifi
penicillium
notatum
produc
activ
agent
name
penicillin
later
penicillin
isol
yellow
powder
use
potent
antibacteri
compound
world
war
ii
use
fleme
method
natur
occur
substanc
chloramphenicol
streptomycin
isol
natur
occur
antibiot
produc
ferment
old
techniqu
trace
back
almost
year
initi
beverag
food
product
beer
one
world
oldest
beverag
produc
barley
ferment
possibl
date
back
sixth
millennium
bc
record
written
histori
ancient
egypt
mesopotamia
anoth
old
ferment
use
initi
koji
process
rice
aspergillu
oryza
past
year
penicillium
roqueforti
util
chees
product
past
year
soy
sauc
asia
bread
egypt
repres
exampl
tradit
ferment
natur
product
industri
applic
produc
primari
secondari
metabol
live
organ
plant
anim
microorgan
owe
technic
improv
screen
program
separ
isol
techniqu
number
natur
compound
discov
exce
million
among
produc
plant
alkaloid
flavonoid
terpenoid
steroid
carbohydr
etc
microbi
origin
report
natur
product
approxim
show
biolog
activ
approxim
obtain
microb
furthermor
biolog
activ
compound
obtain
far
microb
produc
actinomycet
fungi
unicellular
bacteria
increas
role
microorgan
product
antibiot
drug
treatment
seriou
diseas
dramat
howev
develop
resist
microb
tumor
cell
becom
major
problem
requir
much
research
effort
combat
drug
natur
origin
classifi
origin
natur
product
ii
product
deriv
chemic
synthes
natur
product
iii
synthet
product
base
natur
product
structur
evid
import
natur
product
discoveri
lead
develop
drug
treatment
human
diseas
provid
fact
close
half
best
sell
pharmaceut
either
natur
product
deriv
regard
topsel
drug
report
natur
product
deriv
antibiot
today
structur
around
secondari
metabolit
elucid
import
understand
mani
chemic
synthes
drug
owe
origin
natur
sourc
applic
chemic
synthes
natur
metabolit
includ
use
natur
product
deriv
plant
salicycl
acid
deriv
present
white
willow
wintergreen
meadowsweet
reliev
pain
suffer
concoct
plant
administ
hippocr
back
year
bc
even
earlier
egypt
babylonia
fever
pain
childbirth
synthet
salicyl
produc
initi
bayer
later
arthur
eichengrun
bayer
discov
acetyl
deriv
aspirin
reduc
acid
bad
tast
stomach
irrit
plantbas
system
continu
play
essenti
role
health
care
estim
world
health
organ
approxim
world
inhabit
reli
mainli
tradit
medicin
primari
health
care
synthes
compound
origin
natur
product
includ
nonapeptid
design
teprotid
isol
venom
brazilian
pit
viper
bothrop
jararaca
led
design
synthesi
angiotensinconvert
enzym
ace
inhibitor
captopril
first
market
oral
activ
ace
inhibitor
enalapril
anoth
ace
inhibitor
use
treatment
cardiovascular
diseas
approv
market
food
drug
administr
fda
alkaloid
quinin
activ
constitu
fever
tree
cinchona
succirubra
known
centuri
south
american
indian
control
malaria
twentieth
centuri
massiv
program
synthes
quinolin
deriv
base
quinin
prototyp
carri
first
new
quinolon
use
clinic
antibacteri
agent
nalidix
acid
emerg
part
larg
chemic
synthesi
program
develop
sterl
winthrop
research
institut
program
begun
acid
obtain
side
product
purif
chloroquin
found
antibacteri
activ
best
compound
found
program
nalidix
acid
remark
activ
gramneg
bacteria
shown
inhibitor
dna
gyras
discoveri
led
whole
seri
synthet
quinolon
fluoroquinolon
antibiot
pefloxacin
norfloxacin
ciprofloxacin
levofloxacin
ofloxacin
lomefloxacin
sparfloxacin
etc
success
medicin
achiev
major
commerci
success
tabl
import
appreci
quinolon
though
synthet
base
structur
natur
plant
product
quinin
secondari
metabolit
exert
major
impact
control
infecti
diseas
medic
condit
develop
pharmaceut
industri
use
contribut
increas
averag
life
expect
usa
increas
year
year
men
year
women
probabl
import
use
secondari
metabolit
antiinfect
drug
market
antiinfect
us
billion
tabl
us
billion
tabl
show
among
antiinfect
drug
antivir
repres
market
two
antivir
chemic
synthes
today
origin
isol
marin
organ
acyclovir
activ
herp
viru
inhibit
inactiv
dna
polymeras
cytarabin
activ
nonhodgkin
lymphoma
compound
nucleosid
analog
drug
origin
isol
spong
antivir
applic
natur
compound
relat
human
immunodefici
viru
hiv
treatment
pathogenesi
diseas
similar
retrovirus
depend
stabl
integr
host
genom
facilit
effici
replic
viral
rna
mainten
infect
state
therefor
de
novo
viral
dna
synthes
revers
transcript
immedi
integr
host
cell
dna
integr
step
allow
transcript
viral
rna
late
phase
hiv
viral
replic
larg
precursor
polyprotein
gagpol
precursor
pr
must
appropri
cleav
viral
proteas
cleavag
gag
precursor
protein
hiv
critic
matur
infect
viral
particl
without
appropri
cleavag
precursor
polyprotein
noninfecti
viral
particl
gener
produc
confront
problem
tremend
effort
made
us
nation
cancer
institut
nci
search
natur
metabolit
capabl
inhibit
hiv
revers
transcriptas
hiv
proteas
chemic
synthes
deriv
compound
main
agent
use
hiv
furthermor
report
publish
natur
product
inhibitor
hiv
integras
obtain
among
marin
ascidian
alkaloid
lamellarin
produc
mollusk
lamellaria
sp
terrestri
plant
bacchari
genistelloid
achyroclin
satureioid
consist
antihiv
activ
observ
extract
prepar
sever
bacchari
speci
addit
nci
evalu
inhibitori
activ
pepstatin
small
pentapeptid
produc
sever
streptomyc
speci
contain
uniqu
hydroxyamino
acid
statin
steric
block
activ
site
proteas
reason
develop
new
antibiot
new
antibiot
activ
resist
bacteria
requir
bacteria
live
earth
sever
billion
year
time
encount
natur
wide
rang
natur
occur
antibiot
surviv
bacteria
develop
antibiot
resist
mechan
therefor
surpris
becom
resist
natur
antimicrobi
agent
develop
past
year
resist
increasingli
limit
effect
current
antimicrobi
drug
problem
antibiot
resist
also
multidrug
resist
pathogen
bacteria
estim
resist
least
one
current
avail
antibiot
socal
superbug
organ
resist
clinic
use
antibiot
emerg
rapid
rate
aureu
resist
methicillin
respons
mani
case
infect
year
incid
multidrugresist
pathogen
bacteria
increas
infecti
diseas
societi
america
idsa
report
us
hospit
alon
around
million
peopl
acquir
bacteri
infect
year
http
wwwidsocietyorgcontentaspx
aureu
respons
half
hospitalassoci
infect
take
live
approxim
patient
year
usa
alon
bacteria
produc
biofilm
encas
protect
environ
biofilm
grow
wound
scar
tissu
medic
implant
devic
joint
prosthes
spinal
instrument
cathet
vascular
prosthet
graft
heart
valv
bacteri
speci
produc
biofilm
like
resist
least
one
drug
commonli
use
antiinfecti
therapi
call
nosocomi
bacteria
sepsi
case
hospit
caus
gramneg
bacteria
among
pseudomona
aeruginosa
account
almost
opportunist
infect
repres
seriou
problem
patient
hospit
cancer
cystic
fibrosi
burn
caus
death
case
infect
caus
pseudomona
speci
includ
endocard
pneumonia
infect
urinari
tract
central
nervou
system
wound
eye
ear
skin
musculoskelet
system
bacterium
anoth
exampl
natur
multidrugresist
microorgan
although
mani
strain
suscept
gentamicin
tobramycin
amikacin
resist
form
also
develop
multidrugresist
bacteria
make
hospit
danger
place
especi
sick
even
although
see
steadi
increas
resist
almost
everi
pathogen
current
antibiot
time
antibacteri
agent
show
rate
resist
develop
exampl
antimicrobi
rifampicin
target
singl
enzym
suscept
develop
resist
wherea
agent
inactiv
sever
target
irrevers
gener
resist
slowli
addit
antibioticresist
problem
new
famili
antiinfect
compound
need
enter
marketplac
regular
interv
tackl
new
diseas
caus
evolv
pathogen
least
new
diseas
emerg
grow
incid
emerg
infecti
organ
often
encount
host
prior
exposur
thu
repres
novel
challeng
host
immun
system
sever
virus
respons
human
epidem
made
transit
anim
host
human
transmit
human
human
hiv
respons
acquir
immunodefici
syndrom
aid
epidem
one
exampl
although
proven
suspect
sever
acut
respiratori
syndrom
sar
caus
sar
coronaviru
also
evolv
differ
speci
earli
decad
declin
incid
tuberculosi
began
increas
epidem
took
place
owe
inadequ
treatment
regimen
diminish
public
health
system
onset
hivaid
epidem
predict
nearli
billion
peopl
becom
infect
mycobacterium
tuberculosi
diseas
cost
live
million
peopl
sexual
transmit
diseas
also
increas
decad
especi
young
peopl
age
year
human
papillomaviru
chlamydia
genit
herp
gonorrhea
hivaid
exampl
hivaid
infect
million
peopl
world
togeth
diseas
tuberculosi
malaria
hivaid
account
million
ill
million
death
year
addit
evolv
pathogen
includ
ebola
viru
caus
viral
hemorrhag
fever
syndrom
result
mortal
rate
ii
bacterium
legionella
pneumophila
ubiquit
aquat
organ
live
warm
environ
caus
legionnair
diseas
pulmonari
infect
iii
hantaviru
infect
human
two
seriou
ill
hemorrhag
fever
renal
syndrom
hantaviru
pulmonari
syndrom
iv
least
three
speci
bacteria
genu
borrelia
caus
lyme
diseas
emerg
infect
case
infect
acquir
bite
tick
belong
sever
speci
genu
ixod
borrelia
burgdorferi
predomin
caus
lyme
diseas
us
wherea
borrelia
afzelii
borrelia
garinii
implic
european
case
diseas
present
vari
wide
may
includ
rash
flulik
symptom
initi
stage
follow
musculoskelet
arthrit
neurolog
psychiatr
cardiac
manifest
major
case
symptom
elimin
antibiot
especi
treatment
begin
earli
cours
ill
howev
late
inadequ
treatment
lead
latestag
lyme
diseas
disabl
difficult
treat
v
evolv
pathogen
includ
escherichia
coli
enterohemorrhag
e
coli
strain
caus
coliti
bloodi
diarrhea
produc
toxin
call
shiga
toxin
damag
intestin
estim
bacterium
caus
infect
patient
year
usa
anoth
exampl
vi
cryptosporidium
oblig
intracellular
parasit
commonli
found
lake
river
cryptosporidium
parvum
one
common
speci
affect
digest
respiratori
organ
intestin
cryptosporidiosi
character
sever
wateri
diarrhea
pulmonari
tracheal
cryptosporidiosi
human
associ
cough
frequent
lowgrad
fever
peopl
sever
weaken
immun
system
like
sever
persist
symptom
healthi
individu
develop
world
nearli
infecti
diseas
death
caus
six
diseas
diseas
process
acut
respiratori
infect
diarrhea
tuberculosi
hiv
measl
malaria
develop
develop
nation
lead
caus
death
wide
margin
acut
respiratori
diseas
develop
world
acut
respiratori
infect
attribut
primarili
seven
bacteria
bordetella
pertussi
streptococcu
pneumonia
haemophilu
influenza
staphylococcu
aureu
mycoplasma
pneumonia
chlamydophila
pneumonia
chlamydia
trachomati
addit
major
viral
caus
respiratori
infect
includ
respiratori
syncyti
viru
human
parainfluenza
virus
influenza
virus
b
well
adenovirus
diseas
highli
destruct
econom
social
well
human
term
caus
approxim
million
death
per
year
innumer
seriou
ill
besid
affect
econom
growth
develop
prosper
human
societi
mors
identifi
six
gener
factor
emerg
infecti
diseas
ecolog
chang
human
demograph
behavior
intern
travel
technolog
industri
microbi
adapt
chang
breakdown
public
health
measur
one
addit
reason
develop
new
antibiot
relat
toxic
therapeut
agent
use
antibiot
may
also
caus
side
effect
patient
includ
mild
reaction
upset
stomach
vomit
diarrhea
cephalosporin
macrolid
penicillin
tetracyclin
rash
mild
sever
allerg
reaction
cephalosporin
penicillin
sensit
sunlight
tetracyclin
nervous
tremor
seizur
quinolon
side
effect
sever
depend
antibiot
may
disrupt
hear
function
aminoglycosid
kidney
aminoglycosid
polypeptid
liver
rifampin
recent
decad
seen
increas
number
report
progress
develop
bacteri
resist
almost
avail
antimicrobi
agent
major
problem
multidrug
resist
gramneg
bacteria
later
gramposit
bacteria
becam
import
includ
methicillinresist
staphylococci
penicillinresist
pneumococci
vancomycinresist
enterococci
past
solut
problem
depend
primarili
develop
novel
antimicrobi
agent
howev
number
new
class
antimicrobi
agent
develop
decreas
dramat
recent
year
advent
resist
gramposit
bacteria
notic
pharmaceut
biotechnolog
academ
commun
group
make
concert
effort
find
novel
antimicrobi
agent
meet
need
new
glycopeptid
antibiot
teicoplanin
develop
infect
resist
gramposit
bacteria
especi
bacteria
resist
glycopeptid
vancomycin
anoth
instanc
approach
involv
redesign
mixtur
two
compound
call
streptogramin
new
mixtur
call
pristinamycin
allow
administr
drug
parenter
higher
dose
earlier
oral
prepar
two
compon
streptogramin
quinupristin
dalfopristin
chemic
modifi
allow
intraven
administr
new
combin
pristinamycin
approv
fda
use
infect
caus
vancomycinresist
enterococcu
faecium
addit
move
resist
microorgan
glycylcyclin
develop
treat
tetracyclineresist
bacteria
modifi
tetracyclin
show
potent
activ
broad
spectrum
gramposit
gramneg
bacteria
includ
strain
carri
two
major
tetracyclineresist
determin
involv
efflux
ribosom
protect
two
glycylcylin
deriv
dmgmino
dmgdmdot
test
larg
number
clinic
pathogen
isol
variou
sourc
spectrum
activ
compound
includ
organ
resist
antibiot
tetracyclin
exampl
methicillinresist
staphylococci
penicillinresist
pneumonia
vancomycinresist
enterococci
tigecyclin
approv
fda
inject
antibiot
among
novel
class
antimicrobi
agent
use
treat
resist
gramposit
infect
also
mention
cyclic
lipopeptid
antibiot
daptomycin
produc
streptomyc
roseosporu
compound
approv
fda
skin
infect
result
complic
follow
surgeri
diabet
foot
ulcer
burn
repres
first
new
natur
antibiot
approv
mani
year
mode
action
distinct
approv
antibiot
rapidli
kill
gramposit
bacteria
disrupt
multipl
aspect
bacteri
membran
function
bind
irrevers
bacteri
cell
membran
caus
membran
depolar
destroy
ion
concentr
gradient
provok
efflux
k
act
clinic
relev
gramposit
bacteria
staphylococcu
aureu
streptococcu
pyogen
streptococcu
agalactia
streptococcu
dysgalactia
subsp
equisimili
enterococcu
faecali
retain
vitro
potenc
isol
resist
methicillin
vancomycin
linezolid
tradit
infect
treat
penicillin
cephalosporin
resist
agent
becam
widespread
daptomycin
seem
favor
side
effect
profil
might
use
treat
patient
toler
antibiot
telithromycin
macrolid
antibiot
first
oral
activ
compound
new
famili
antibacteri
name
ketolid
show
potent
activ
pathogen
implic
communityacquir
respiratori
tract
infect
irrespect
blactam
macrolid
fluoroquinolon
suscept
microorgan
suscept
antibiot
pneumococci
h
influenza
moraxella
catarrhali
includ
blactamaseposit
strain
addit
telithromycin
low
potenti
select
resist
isol
induct
crossresist
found
macrolid
clavulan
acid
first
detect
streptomyc
clavuligeru
contain
bicycl
blactam
ring
fuse
oxazolidin
ring
oxygen
place
sulfur
bhydroxyethyliden
substitu
acylamino
group
first
describ
shown
potent
inhibitor
blactamas
produc
staphylococci
plasmidmedi
blactamas
e
coli
klebsiella
proteu
shigella
pseudomona
haemophilu
although
broadspectrum
antibiot
clavulan
acid
possess
low
antibacteri
activ
therefor
molecul
combin
blactamas
inhibitor
varieti
broadspectrum
semisynthet
penicillin
exampl
administ
amoxicillin
use
treatment
infect
caus
blactamaseproduc
pathogen
bacteria
world
sale
us
billion
second
largest
sell
antibacteri
drug
clavulan
acid
also
combin
ticarcillin
penicillin
effect
organ
e
coli
proteu
salmonella
haemophilu
pseudomona
aureu
normal
use
hospit
treat
sever
infect
affect
blood
intern
organ
bone
joint
upper
lower
airway
skin
soft
tissu
combin
extend
ticarcillin
antimicrobi
activ
inhibit
action
blactamas
produc
certain
bacteria
mycosi
condit
fungi
pass
resist
barrier
human
anim
bodi
establish
infect
organ
harmless
time
sometim
caus
fungal
infect
case
infect
life
threaten
howev
deepli
invas
dissemin
lead
seriou
infect
particularli
critic
ill
patient
elderli
peopl
condit
affect
immun
system
diseas
use
immunosuppress
agent
addit
use
antineoplast
broadspectrum
antibiot
prosthet
devic
graft
aggress
surgeri
increas
invas
fungal
infect
patient
burn
neutropenia
pancreat
organ
transplant
liver
transplant
heart
transplant
kidney
transplant
also
predispos
fungal
infect
approxim
death
nosocomi
infect
caus
fungi
caus
candida
aspergillu
although
cryptococcu
spp
fusarium
spp
scedosporium
spp
penicillium
spp
zygomycet
increasingli
involv
pulmonari
aspergillosi
main
factor
involv
death
recipi
bone
marrow
transplant
pneumocysti
carinii
lead
caus
death
aid
patient
europ
north
america
rise
incid
invas
fungal
infect
emerg
broader
fungal
resist
led
need
novel
antifung
agent
amphotericin
b
firstlin
therapi
system
infect
broad
spectrum
fungicid
activ
howev
consider
side
effect
limit
clinic
util
echinocandin
larg
lipopeptid
molecul
inhibit
synthesi
key
compon
fungal
cell
wall
three
echinocandin
caspofungin
micafungin
anidulafungin
reach
market
caspofungin
also
known
pneumocandin
compound
first
cellwallact
antifung
approv
new
inject
antifung
irrevers
inhibit
synthas
prevent
format
glucan
polym
disrupt
integr
fungal
cell
wall
activ
less
toxic
amphotericin
b
show
broad
spectrum
activ
candida
includ
fluconozol
resist
aspergillu
histoplasma
p
carinii
major
caus
hiv
death
micafungin
licens
clinic
use
asian
countri
us
compound
exhibit
extrem
potent
antifung
activ
clinic
import
fungi
includ
aspergillu
azoleresist
strain
candida
anim
studi
micafungin
efficaci
amphotericin
b
respect
improv
surviv
rate
character
linear
pharmacokinet
profil
substanti
fewer
toxic
effect
anidulafungin
current
licens
us
although
sever
new
antifung
drug
develop
past
year
patient
remain
resist
treatment
main
reason
includ
intrins
acquir
antifung
resist
organ
dysfunct
prevent
use
agent
drug
interact
addit
drug
penetr
poorli
sanctuari
site
includ
eye
urin
other
associ
consider
advers
event
howev
progress
posaconazol
new
member
triazol
class
antifung
shown
clinic
efficaci
treatment
oropharyng
candidiasi
potenti
salvag
therapi
invas
aspergillosi
zygomycosi
cryptococc
mening
varieti
fungal
infect
avail
oral
suspens
favor
toxic
profil
wide
spectrum
posaconazol
activ
vitro
studi
anim
model
preliminari
clinic
studi
suggest
repres
import
addit
antifung
armamentarium
addit
screen
program
antibacteri
activ
pharmaceut
industri
extend
program
diseas
area
microorgan
prolif
sourc
structur
divers
bioactiv
metabolit
yield
import
product
pharmaceut
industri
microbi
secondari
metabolit
use
applic
antibacteri
antifung
antivir
infect
exampl
immunosuppress
revolution
medicin
facilit
organ
transplant
applic
includ
antitumor
drug
enzym
inhibitor
gastrointestin
motor
stimul
agent
hypocholesterolem
drug
rumin
growth
stimul
insecticid
herbicid
coccidiostat
antiparasit
vs
coccidia
helminth
pharmacolog
activ
applic
possibl
variou
area
pharmacolog
agricultur
develop
catalyz
use
simpl
enzym
assay
screen
test
intact
anim
field
year
approxim
million
new
case
cancer
diagnos
world
result
million
cancerrel
death
tumor
type
highest
incid
lung
breast
colorect
microbi
metabolit
among
import
cancer
chemotherapeut
agent
start
appear
around
discoveri
actinomycin
sinc
mani
compound
anticanc
properti
isol
natur
sourc
current
compound
antineoplas
activ
origin
isol
natur
product
deriv
among
approv
product
deserv
special
attent
actinomycin
anthracyclin
daunorubicin
doxorubicin
epirubicin
pirirubicin
valrubicin
bleomycin
mitosan
mitomycin
c
anthracenon
mithramycin
streptozotocin
pentostatin
enediyn
calcheamycin
taxol
epothilon
actinomycin
oldest
microbi
metabolit
use
cancer
therapi
rel
actinomycin
first
antibiot
isol
actinomycet
latter
obtain
actinomyc
antibioticu
streptomyc
antibioticu
waksman
woodruff
bind
dna
transcript
initi
complex
prevent
elong
rna
polymeras
properti
howev
confer
human
toxic
use
primarili
investig
tool
develop
molecular
biolog
despit
toxic
howev
serv
well
wilm
tumor
children
anthracyclin
effect
antitumor
compound
develop
effect
type
cancer
class
chemotherapi
agent
use
treat
wide
rang
cancer
includ
leukemia
lymphoma
breast
uterin
ovarian
lung
cancer
anthracyclin
act
intercal
dna
strand
result
complex
format
inhibit
synthesi
dna
rna
also
trigger
dna
cleavag
topoisomeras
ii
result
mechan
lead
cell
death
cytotox
effect
bind
cell
membran
plasma
protein
play
import
role
main
advers
effect
heart
damag
cardiotox
consider
limit
use
vomit
first
anthracyclin
discov
daunorubicin
daunomycin
produc
natur
streptomyc
peucetiu
doxorubicin
adriamycin
develop
anoth
anthracyclin
epirubicin
compound
approv
fda
favor
doxorubicin
chemotherapi
regimen
appear
caus
fewer
side
effect
epirubicin
differ
spatial
orient
hydroxyl
group
carbon
sugar
may
account
faster
elimin
reduc
toxic
epirubicin
primarili
use
breast
ovarian
cancer
gastric
cancer
lung
cancer
lymphoma
valrubicin
semisynthet
analog
doxorubicin
approv
chemotherapeut
drug
use
treat
bladder
cancer
bleomycin
nonribosom
glycopeptid
microbi
metabolit
produc
famili
structur
relat
compound
bacterium
streptomyc
verticillu
first
report
umezawa
et
al
bleomycin
obtain
fda
approv
use
anticanc
agent
induc
dna
strand
break
chemotherapeut
form
primarili
bleomycin
mitosan
compos
sever
mitomycin
form
cultiv
streptomyc
caespitosu
although
mitosan
excel
antitumor
agent
limit
util
owe
toxic
mitomycin
c
approv
fda
show
activ
sever
type
cancer
lung
breast
bladder
anal
colorect
head
neck
includ
melanoma
gastric
pancreat
neoplasm
recent
mitomycin
dimer
explor
potenti
altern
lower
toxic
increas
effici
mithramycin
plicamycin
antitumor
aromat
polyketid
produc
streptomyc
argillac
show
antibacteri
antitumor
activ
one
older
chemotherapi
drug
use
treatment
testicular
cancer
dissemin
neoplasm
hypercalcemia
bind
gcrich
dna
sequenc
inhibit
bind
transcript
factor
believ
affect
neuron
survivaldeath
pathway
may
also
indirectli
regul
gene
transcript
alter
histon
methyl
repeat
use
organotox
kidney
liver
hematopoiet
system
becom
problem
streptozotocin
microbi
metabolit
antitumor
properti
produc
streptomyc
achromogen
chemic
glucosaminenitrosourea
compound
alkyl
agent
nitrosourea
class
toxic
cell
caus
damag
dna
although
mechan
may
also
contribut
compound
select
toxic
bcell
pancreat
islet
similar
enough
glucos
transport
cell
glucos
transport
protein
cell
recogn
glucos
transport
bcell
rel
high
level
glucos
permeas
rel
streptozotocin
toxic
bcell
explain
fda
grant
approv
streptozotocin
treatment
pancreat
islet
cell
cancer
pentostatin
deoxycoformycin
anticanc
chemotherapeut
drug
produc
antibioticu
classifi
purin
analog
mimic
nucleosid
adenosin
thu
tightli
bind
inhibit
adenosin
deaminas
k
interfer
cell
abil
process
dna
pentostatin
commonli
use
treat
hairi
cell
leukemia
acut
lymphocyt
leukemia
prolymphocyt
leukemia
band
tcell
origin
tcell
leukemia
lymphoma
howev
caus
kidney
liver
lung
neurolog
toxic
fda
grant
approv
pentostatin
calicheamicin
highli
potent
antitumor
microbi
metabolit
enediyn
famili
produc
micromonospora
echinospora
antitumor
activ
appar
due
cleavag
doublestrand
dna
highli
toxic
possibl
introduc
one
compound
clinic
attach
antibodi
deliv
certain
cancer
type
select
ingeni
idea
wyeth
laboratori
avoid
side
effect
calicheamicin
regard
gemtuzumab
effect
acut
myelogen
leukemia
aml
calicheamicin
bound
monoclon
antibodi
transmembran
receptor
express
cell
monocyticmyeloid
lineag
express
leukem
blast
cell
normal
hematopoiet
cell
intens
diminish
matur
approv
fda
use
patient
age
year
relaps
aml
consid
candid
standard
chemotherapi
success
nonactinomycet
molecul
taxol
paclitaxel
first
isol
pacif
yew
tree
taxu
brevifolia
also
produc
endophyt
fungi
taxomyc
andreana
nodulisporium
sylviform
compound
inhibit
rapidli
divid
mammalian
cancer
cell
promot
tubulin
polymer
interf
normal
microtubul
breakdown
cell
divis
drug
also
inhibit
sever
fungi
pythium
phytophthora
aphanomyc
mechan
taxol
approv
refractori
ovarian
cancer
today
use
breast
advanc
form
kaposi
sarcoma
new
formul
avail
paclitaxel
bound
albumin
taxol
sale
amount
us
billion
bristol
myerssquibb
repres
compani
pharmaceut
sale
third
largest
sell
product
current
taxol
product
use
plant
cell
ferment
technolog
epothilon
name
deriv
molecular
featur
epoxid
thiazol
keton
macrolid
origin
isol
broth
soil
myxobacterium
sorangium
cellulosum
weak
agent
rust
fungi
identifi
microtubulestabil
drug
act
similar
manner
taxol
howev
gener
time
potent
taxol
inhibit
cell
growth
cultur
five
analog
undergo
investig
candid
anticanc
drug
preclin
studi
indic
broad
spectrum
antitumor
activ
includ
taxolresist
tumor
cell
best
current
avail
therapi
median
surviv
time
patient
metastat
breast
cancer
year
mani
patient
develop
resist
taxan
chemotherapi
drug
one
epothilon
ixabepilon
approv
octob
fda
use
treatment
aggress
metastat
local
advanc
breast
cancer
longer
respond
current
avail
chemotherapi
tumor
cell
pglycoprotein
reduc
intracellular
antitumor
drug
concentr
therebi
limit
access
chemotherapeut
substrat
site
action
epothilon
attract
activ
pglycoproteinproduc
tumor
good
solubl
epothilon
b
polyketid
macrolacton
methylthiazol
group
connect
macrocycl
olefin
bond
testicular
cancer
common
cancer
diagnosi
men
age
year
approxim
case
detect
unit
state
annual
major
testicular
neoplasm
germ
cell
tumor
rel
uncommon
carcinoma
account
male
malign
remark
progress
made
medic
treatment
advanc
testicular
cancer
substanti
increas
cure
rate
approxim
earli
almost
today
cure
rate
highest
solid
tumor
improv
surviv
primarili
due
effect
chemotherapi
major
advanc
chemotherapi
testicular
germ
cell
tumor
introduct
cisplatin
two
chemotherapi
regimen
effect
patient
good
testicular
germ
cell
tumor
prognosi
four
cycl
etoposid
cisplatin
three
cycl
bleomycin
etoposid
cisplatin
latter
three
agent
bleomycin
etoposid
natur
product
enzym
inhibitor
receiv
increas
attent
use
tool
studi
enzym
structur
reaction
mechan
also
potenti
util
medicin
agricultur
sever
enzym
inhibitor
variou
industri
use
isol
microb
import
clavulan
acid
inhibitor
blactamas
discuss
section
move
antibiot
resist
develop
bacteria
statin
hypocholesterolem
drug
present
section
hypocholesterolem
drug
common
target
inhibitor
glucosidas
amylas
lipas
proteas
xanthin
oxidas
xo
acarbos
pseudotetrasaccharid
made
actinoplan
sp
contain
aminocyclitol
moieti
valienamin
inhibit
intestin
aglucosidas
sucras
result
decreas
starch
breakdown
intestin
use
combat
diabet
human
amylas
inhibitor
use
control
carbohydratedepend
diseas
diabet
obes
hyperlipemia
amylas
inhibitor
also
known
starch
blocker
contain
substanc
prevent
dietari
starch
absorb
bodi
inhibitor
may
also
use
weight
loss
version
amylas
inhibitor
show
potenti
reduc
carbohydr
absorpt
human
use
amylas
inhibitor
treatment
rumen
acidosi
also
report
exampl
microbi
aamylas
inhibitor
paim
obtain
cultur
filtrat
streptomyc
corchorushii
taia
taib
oligosaccharid
compound
streptomyc
calvu
lipstatin
pancreat
lipas
inhibitor
produc
streptomyc
toxytricini
use
combat
obes
diabet
interfer
gastrointestin
absorpt
fat
commerci
product
tetrahydrolipstatin
also
known
orlistat
pathogen
process
diseas
emphysema
arthriti
pancreat
cancer
aid
proteas
inhibitor
potenti
power
tool
inactiv
target
proteas
exampl
microbi
product
includ
antipain
produc
streptomyc
yokosukaensi
leupeptin
streptomyc
roseochromogen
chymostatin
streptomyc
hygroscopicu
leupeptin
produc
speci
actinomycet
xo
catalyz
oxid
hypoxanthin
uric
acid
xanthin
excess
accumul
uric
acid
blood
call
hyperuricemia
caus
gout
inhibitor
xo
decreas
uric
acid
level
result
antihyperuricem
effect
potent
inhibitor
xo
hydroxyakalon
purifi
ferment
broth
agrobacterium
aurantiacum
sp
nov
marin
bacteri
strain
fungal
product
also
use
enzym
inhibitor
cancer
diabet
poison
alzheim
diseas
etc
enzym
inhibit
includ
acetylcholinesteras
protein
kinas
tyrosin
kinas
glycosidas
other
immunosuppres
suppressor
cell
critic
regul
normal
immun
respons
individu
immun
system
capabl
distinguish
nativ
foreign
antigen
mount
respons
latter
major
role
establish
suppressor
lymphocyt
phenomenon
suppressor
cell
also
play
role
regul
magnitud
durat
specif
antibodi
respons
antigen
challeng
suppress
immun
respons
either
drug
radiat
prevent
reject
graft
transplant
control
autoimmun
diseas
call
immunosuppress
number
microbi
compound
capabl
suppress
immun
respons
discov
cyclosporin
origin
introduc
narrowspectrum
antifung
peptid
produc
mold
tolypocladium
nivenum
origin
classifi
trichoderma
polysporum
later
tolypocladium
inflatum
aerob
ferment
cyclosporin
famili
neutral
highli
lipophil
cyclic
undecapeptid
contain
unusu
amino
acid
synthes
nonribosom
peptid
synthetas
cyclosporin
synthetas
discoveri
immunosuppress
activ
led
use
heart
liver
kidney
transplant
overwhelm
success
organ
transplant
field
cyclosporin
approv
use
thought
bind
cytosol
protein
cyclophilin
immunophilin
immunocompet
lymphocyt
especi
lymphocyt
complex
cyclosporin
cyclophilin
inhibit
calcineurin
normal
circumst
respons
activ
transcript
also
inhibit
lymphokin
product
interleukin
releas
therefor
lead
reduc
function
effector
cell
sale
cyclosporin
reach
us
billion
per
year
import
transplant
agent
includ
sirolimu
rapamycin
tacrolimu
produc
actinomycet
rapamycin
especi
use
kidney
transplant
lack
nephrotox
seen
cyclosporin
tacrolimu
macrolid
first
discov
product
hygroscopicu
initi
propos
antifung
agent
howev
abandon
discov
potent
immunosuppress
antiprolif
properti
compound
bind
immunophilin
protein
binari
complex
interact
rapamycinbind
domain
inactiv
serinethreonin
kinas
term
mammalian
target
rapamycin
latter
known
control
protein
regul
mrna
translat
initi
progress
antiprolif
effect
rapamycin
also
use
conjunct
coronari
stent
prevent
restenosi
usual
occur
treatment
coronari
arteri
diseas
balloon
angioplasti
rapamycin
also
show
promis
treat
tuber
sclerosi
complex
tsc
congenit
disord
leav
suffer
prone
benign
tumor
growth
brain
heart
kidney
skin
organ
studi
rapamycin
treatment
tsc
univers
california
lo
angel
ucla
research
observ
major
improv
mice
regard
retard
relat
autism
rapamycin
poor
aqueou
solubl
analog
everolimu
tensirolimu
ariad
develop
improv
pharmaceut
properti
everolimu
current
use
immunosuppress
prevent
reject
organ
transplant
although
fda
approv
usa
approv
use
europ
australia
phase
iii
trial
conduct
us
everolimu
may
role
heart
transplant
shown
reduc
chronic
allograft
vasculopathi
transplant
everolimu
also
use
drugelut
coronari
stent
immunosuppress
prevent
reject
rapamycin
ester
convert
rapamycin
vivo
rapamycin
analog
current
investig
phase
ii
trial
recurr
endometri
cancer
singl
agent
phase
iii
trial
treatment
glioblastoma
combin
inhibitor
certain
epiderm
growth
factor
receptor
vascular
endotheli
growth
factor
receptor
famili
member
novel
nonprodrug
rapamycin
analog
nonlinear
pharmacokinet
behavior
demonstr
antiprolif
activ
sever
human
tumor
cell
line
vitro
experiment
tumor
vivo
agent
current
evalu
phase
iii
trial
includ
patient
differ
tumor
two
addit
smallmolecul
rapamycin
analog
current
preclin
develop
treatment
bone
metastas
primari
bone
cancer
tacrolimu
discov
japan
produc
streptomyc
tsukubaensi
howev
use
almost
abandon
doseassoci
toxic
dr
thoma
starzl
univers
pittsburgh
rescu
use
lower
dose
realiz
approxim
time
activ
immunosuppress
cyclosporin
introduc
japan
approv
fda
use
immunosuppress
liver
transplant
furthermor
use
extend
includ
bone
marrow
cornea
heart
intestin
kidney
lung
pancrea
trachea
small
bowel
skin
limb
transplant
prevent
graftvshost
diseas
topic
also
use
atop
dermat
widespread
skin
diseas
laboratori
tacrolimu
inhibit
mix
lymphocyt
reaction
format
lymphocyt
format
solubl
mediat
includ
interferon
g
recent
report
tacrolimu
inhibit
tumor
growth
factorbinduc
signal
collagen
synthesi
human
lung
fibroblast
cell
factor
play
pivot
role
tissu
fibrosi
includ
pulmonari
fibrosi
therefor
tacrolimu
may
use
treatment
pulmonari
fibrosi
although
use
acut
inflammatori
phase
may
exacerb
lung
injuri
hypocholesterolem
drug
atherosclerosi
gener
view
chronic
progress
diseas
character
continu
accumul
atheromat
plaqu
within
arteri
wall
past
two
decad
wit
introduct
varieti
antiatherosclerot
therapi
statin
form
class
hypolipidem
drug
use
lower
cholesterol
inhibit
enzym
hmgcoa
reductas
ratelimit
enzym
mevalon
pathway
cholesterol
biosynthesi
inhibit
enzym
liver
stimul
lowdens
lipoprotein
ldl
receptor
result
increas
clearanc
ldl
bloodstream
decreas
blood
cholesterol
level
cholesterollow
effect
reduc
risk
cardiovascular
diseas
prevent
stroke
reduc
develop
peripher
vascular
diseas
addit
antithrombot
antiinflammatori
current
number
statin
clinic
use
entir
group
statin
reach
annual
market
nearli
us
billion
becam
gener
pharmaceut
first
member
group
compactin
mevastatin
isol
antibiot
product
penicillium
brevicompactum
later
penicillium
citrinum
although
commerci
import
compactin
deriv
achiev
overwhelm
medic
commerci
success
ethyl
form
known
lovastatin
monacolin
k
mevinolin
isol
broth
monascu
ruber
aspergillu
terreu
lovastatin
first
commerci
market
statin
approv
fda
semisynthet
deriv
lovastatin
simvastatin
major
hypocholesterolem
drug
sell
us
billion
per
year
becom
gener
anoth
statin
pravastatin
us
billion
per
year
made
differ
biotransform
process
compactin
streptomyc
carbophilu
actinomadura
sp
genera
involv
product
statin
doratomyc
eupenicillium
gymnoascu
hypomyc
paecilomyc
phoma
trichoderma
pleurotu
synthet
compound
model
structur
natur
statin
atorvastin
lead
drug
entir
pharmaceut
industri
term
market
share
approxim
us
billion
per
year
mani
year
insecticid
pesticid
use
insect
development
form
includ
ovicid
larvicid
use
egg
larva
insect
respect
insecticid
use
agricultur
medicin
industri
household
use
insecticid
believ
one
major
factor
behind
increas
agricultur
product
twentieth
centuri
synthet
insecticid
pose
hazard
wherea
natur
insecticid
offer
adequ
level
pest
control
pose
fewer
hazard
microbi
produc
insecticid
especi
valuabl
toxic
nontarget
anim
human
extrem
low
compar
commonli
use
insecticid
safe
pesticid
user
consum
treat
crop
action
microbi
insecticid
often
specif
singl
group
speci
insect
specif
mean
microbi
insecticid
natur
affect
benefici
insect
includ
predat
parasit
pest
treat
area
spinosyn
group
group
natur
product
produc
saccharopolyspora
spinosa
discov
research
isol
spinosyn
well
minor
analog
activ
wide
varieti
insect
pest
especi
lepidopteran
dipteran
antibiot
activ
compound
attack
nervou
system
insect
target
two
key
neurotransmitt
receptor
crossresist
known
insecticid
spinosyn
famili
macrolid
carbon
atom
contain
four
connect
ring
carbon
atom
core
two
deoxysugar
forosamin
triomethylrhamnos
requir
bioactiv
attach
novel
spinosyn
prepar
biotransform
use
genet
engin
strain
saccharopolyspora
erythraea
mixtur
spinosyn
spinosad
produc
ferment
introduc
market
control
chew
insect
varieti
crop
spinosyn
formul
recent
approv
use
organ
crop
anim
health
applic
recent
new
natur
occur
seri
insectact
compound
discov
novel
soil
isol
saccharopolyspora
pogona
cultur
produc
uniqu
famili
new
spinosyn
butenyl
substitut
posit
spinosyn
lacton
name
butenylspinosyn
pogonin
herbicid
chemic
market
inhibit
interrupt
normal
plant
growth
develop
wide
use
agricultur
industri
urban
area
weed
manag
approxim
kind
weed
wide
distribut
world
yield
loss
caus
kind
weed
approxim
total
crop
product
everi
year
herbicid
provid
costeffect
weed
control
minimum
labor
use
crop
plant
larg
acreag
soy
cotton
corn
canola
numer
class
herbicid
differ
mode
action
well
differ
potenti
advers
effect
health
environ
past
centuri
chemic
herbicid
use
control
variou
weed
may
caus
mani
seriou
side
effect
injur
crop
threat
applic
other
expos
chemic
herbicideresist
weed
popul
reduct
soil
water
qualiti
herbicid
residu
detriment
effect
nontarget
organ
exampl
alachlor
atrazin
report
caus
cancer
anim
test
increas
global
environment
conscious
bioherbicid
highli
effect
weed
control
environment
friendli
well
attract
research
applic
microbi
herbicid
divid
microbi
prepar
microorgan
control
weed
microbi
deriv
herbicid
first
microbi
herbicid
independ
discov
germani
japan
group
germani
isol
phosphinothricin
tripeptid
peptid
antibiot
consist
two
molecul
lalanin
one
molecul
unusu
amino
acid
lphosphinothricin
n
hydroxyl
methyl
phosphinoyl
homoalanyl
alanylalanin
isol
streptomyc
viridochromogen
broadspectrum
antibacteri
includ
activ
botryti
cinerea
japan
discov
meiji
seiki
laboratori
hygroscopicu
name
bialapho
bioactiv
lphosphinothricin
structur
analog
glutam
acid
act
competit
inhibitor
glutamin
synthetas
bactericid
gramposit
gramneg
bacteria
fungicid
b
cinerea
herbicid
properti
glufosin
dlphosphinothricin
without
alaala
develop
herbicid
therefor
agent
act
herbicid
without
alaala
bialapho
influenc
microorgan
soil
easili
degrad
environ
halflif
h
low
level
environment
impact
great
interest
environmentalist
global
anim
health
market
valu
us
billion
deriv
parasiticid
parasit
organ
inhabit
bodi
benefit
prolong
close
associ
host
antiparasit
compound
inhibit
growth
reproduct
parasit
antiparasit
directli
kill
parasit
gener
parasit
much
smaller
host
show
high
degre
special
mode
life
reproduc
quickli
greater
number
host
classic
exampl
parasit
includ
interact
vertebr
host
divers
anim
tapeworm
fluke
plasmodium
speci
flea
parasit
infect
caus
potenti
seriou
health
problem
even
kill
host
parasit
mainli
enter
bodi
mouth
usual
ingest
taint
food
drink
common
problem
tropic
area
limit
region
varieti
parasit
four
major
categori
protozoa
trematoda
cestoda
nematoda
major
group
includ
protozoan
organ
one
cell
parasit
worm
helminth
infect
digest
tract
sometim
two
caus
infect
time
report
approxim
world
popul
infect
roundworm
addit
major
agricultur
problem
infect
farm
anim
worm
predomin
type
antiparasit
screen
effort
year
test
synthet
compound
nematod
commerci
product
result
certain
antibiot
also
shown
possess
antihelmint
activ
nematod
cestod
fail
compet
synthet
compound
although
merck
earlier
develop
commerci
use
synthet
product
thiabendazol
enough
foresight
examin
microbi
broth
antihelmint
activ
found
nontox
ferment
broth
kill
intestin
nematod
nematosporoid
dubiu
mice
streptomyc
avermitili
cultur
isol
mura
cowork
kitasato
institut
japan
produc
famili
secondari
metabolit
eight
compound
antihelmint
insecticid
activ
compound
name
avermectin
pentacycl
macrocycl
lacton
harbor
disaccharid
methyl
sugar
oleandros
except
activ
parasit
especi
nemathelminth
nematod
arthropod
parasit
time
higher
known
synthet
antihelmint
agent
surprisingli
avermectin
lack
activ
bacteria
fungi
inhibit
protein
synthesi
ionophor
instead
interfer
neurotransmiss
mani
invertebr
caus
paralysi
death
neuromuscular
attack
annual
market
avermectin
surpass
us
billion
use
nematod
arthropod
parasit
sheep
cattl
dog
hors
swine
semisynthet
deriv
ivermectin
time
activ
thiabendazol
commerci
veterinari
product
efficaci
ivermectin
made
promis
candid
control
human
onchocerciasi
human
strongyloidiasi
anoth
avermectin
call
doramectin
cyclohexyl
avermectin
produc
mutat
biosynthesi
commerci
use
food
anim
semisynthet
monosaccharid
deriv
doramectin
call
selamectin
recent
commerci
avermectin
activ
heartworm
dirofilaria
immiti
flea
companion
anim
although
macrocycl
backbon
molecul
ivermectin
doramectin
selamectin
ident
differ
substitut
pharmacolog
relev
site
avermectin
close
relat
milbemycin
group
nonglycosid
macrolid
produc
hygroscopicu
subsp
aureolacrimosu
compound
possess
activ
worm
insect
coccidiostat
use
prevent
coccidiosi
extens
intens
rear
poultri
coccidiosi
name
given
common
intestin
diseas
caus
invad
protozoan
parasit
genu
eimeria
affect
sever
differ
anim
speci
cattl
dog
cat
poultri
etc
major
damag
caus
rapid
multipl
parasit
intestin
wall
subsequ
ruptur
cell
intestin
line
lead
high
mortal
sever
loss
product
coccidia
oblig
intracellular
parasit
show
host
specif
cattl
coccidia
caus
diseas
cattl
speciesspecif
coccidia
mani
year
synthet
compound
use
combat
coccidiosi
poultri
howev
resist
develop
rapidli
solut
came
scene
discoveri
narrowspectrum
polyeth
antibiot
monensin
extrem
potenc
coccidian
made
streptomyc
cinnamonensi
monensin
led
way
addit
microbi
ionophor
antibiot
lasalocid
narasin
salinomycin
produc
variou
streptomyc
speci
form
complex
polar
cation
k
na
ca
mg
sever
affect
osmot
balanc
parasit
cell
thu
caus
death
widespread
use
anticoccidi
revolution
poultri
industri
reduc
mortal
product
loss
caus
coccidiosi
great
interest
anoth
extrem
valuabl
applic
monensin
growth
promot
rumin
synthet
chemic
test
year
inhibit
wast
methan
product
cattl
sheep
increas
fatti
acid
format
especi
propion
improv
feed
effici
howev
fail
solut
monensin
becam
major
success
rumin
growth
enhanc
year
certain
antibiot
use
foodanim
product
enhanc
feed
util
weight
gain
product
standpoint
feed
antibiot
consist
shown
improv
anim
weight
gain
feed
effici
especi
younger
anim
respons
probabl
deriv
inhibitori
effect
normal
microbiota
lead
reduc
intestin
inflamm
improv
nutrient
util
pig
usa
expos
great
varieti
antibiot
includ
blactam
antibiot
includ
penicillin
lincosamid
macrolid
includ
erythromycin
tetracyclin
group
member
use
treat
infect
human
addit
bacitracin
flavophospholipol
pleuromutilin
quinoxalin
virginiamycin
util
growth
stimul
flavophospholipol
virginiamycin
also
use
growth
promot
poultri
describ
cattl
also
expos
ionophor
monensin
promot
growth
anim
health
institut
america
estim
without
use
growthpromot
antibiot
usa
would
requir
addit
million
chicken
million
cattl
million
pig
reach
level
product
attain
current
practic
consid
anim
health
research
develop
new
antiinfect
product
discoveri
decreas
discoveri
new
antibiot
decreas
past
year
new
drug
approv
therefor
incumb
veterinari
practition
use
exist
product
respons
manner
ensur
longev
remain
seen
effect
dearth
new
antibiot
veterinari
medicin
futur
practic
veterinari
medicin
product
agricultur
food
safeti
public
health
sinc
eu
decis
prohibit
antibiot
use
foodanim
growth
promot
four
antibiot
growth
promot
ban
includ
macrolid
drug
tylosin
spiramycin
although
macrolid
longer
formal
use
growth
promot
use
veterinari
prescript
risen
ton
ton
suggest
use
prohibit
well
known
effect
rout
feed
via
gastrointestin
tract
mani
critic
ill
patient
accept
earli
feed
improv
health
postop
patient
gastric
stasi
excess
volum
stomach
increas
risk
aspir
subsequ
pneumonia
account
import
achiev
earli
adequ
nutrit
intak
common
practic
mani
intens
care
unit
use
drug
improv
gastrointestin
motil
erythromycin
macrolid
antibiot
broad
spectrum
activ
well
recogn
prescrib
either
intraven
oral
caus
side
effect
diarrhea
nausea
vomit
side
effect
part
due
action
erythromycin
motilin
receptor
gut
make
antibiot
attract
use
ill
patient
gastrointestin
motil
problem
develop
erythromycin
analog
lack
antibiot
action
retain
action
motilin
receptor
name
motilid
recent
oral
activ
erythromycinderiv
motilin
receptor
agonist
mitemcin
test
patient
idiopath
diabet
gastroparesi
case
improv
gastroparet
symptom
observ
contribut
microorgan
medicin
agricultur
overwhelm
howev
antibiot
resist
microb
creat
danger
situat
need
new
antibiot
clear
unfortun
larg
pharmaceut
compani
abandon
search
new
antimicrobi
compound
owe
econom
conclud
drug
direct
chronic
diseas
offer
better
revenu
stream
antimicrobi
agent
latter
length
treatment
short
govern
restrict
like
small
pharmaceut
biotechnolog
compani
develop
antibiot
depend
ventur
capit
rather
sale
incom
present
regul
face
huge
barrier
enter
market
barrier
rais
best
intent
ensur
public
safeti
opposit
effect
termin
antibiot
develop
resist
continu
increas
howev
bright
possibl
one
promis
util
uncultiv
microorgan
consid
bacteria
fungi
cultiv
laboratori
put
effort
find
mean
grow
microorgan
proceed
succeed
furthermor
research
extract
bacteri
dna
soil
marin
habitat
clone
larg
fragment
exampl
bacteri
artifici
chromosom
express
host
bacterium
screen
librari
new
antibiot
metagenom
effort
allow
access
vast
untap
reservoir
genet
metabol
divers
could
result
discoveri
new
use
natur
product
addit
two
rel
new
techniqu
chemic
biolog
modif
old
antibiot
could
still
suppli
new
power
drug
comment
also
appli
nonantibiot
antitumor
agent
microbi
product
